Hair relaxer class action over reimbursement for products can move forward, judge says
By Diana Novak Jones
Sept 30 (Reuters) -The judge overseeing the sprawling litigation over claims that chemical hair relaxer products made by L'Oreal USA, Revlon and others cause cancer refused to dismiss a proposed class action brought by consumers seeking reimbursement for products they say they would not have purchased had they known of the risks.
U.S. District Judge Mary Rowland in Illinois on Friday largely rejected L’Oreal, Revlon, Namasté Laboratories and other companies’ bid to dismiss the consolidated consumer class action, which seeks economic damages for the products purchased, punitive damages and medical monitoring funds for some plaintiffs who say they are at increased risk for uterine cancer and other health problems because of their use of the products.
The class action represents a different prong of the litigation over hair relaxer products, which includes thousands of lawsuits filed by women who say the products caused their uterine cancer and other health problems.
The proposed economic damages class would cover any U.S. consumer who purchased the products. The medical monitoring class would cover consumers in certain states who used the products at least four times a year and had not been diagnosed with uterine or ovarian cancer.
Attorneys for the companies did not immediately respond to requests for comment on Monday, nor did attorneys for the consumers.
The products, which include chemicals to permanently straighten textured hair, are typically marketed to women of color. The first lawsuits hit court dockets after the October 2022 publication of a National Institutes of Health study that found women who used the products multiple times a year were more than twice as likely to develop uterine cancer.
In a statement posted online after the first lawsuits were filed, L'Oreal said it was "confident in the safety of our products and believe the recent lawsuits filed against us have no legal merit."
A Revlon representative previously told Reuters the company did not “believe the science supports a link between chemical hair straighteners or relaxers and cancer.”
Rowland has already rejected the companies’ separate effort to dismiss the injury claims in the litigation, which includes 8,500 lawsuits, according to recent data from the Judicial Panel on Multidistrict Litigation.
In November, Rowland said the plaintiffs had put forward sufficient facts to support their allegations accusing the companies of negligence, defective design of the products and failure to warn customers of the risks.
Reporting by Diana Jones
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
